PMID: 11604574Oct 18, 2001Paper

Cellular therapy: donor lymphocyte infusion

Current Opinion in Hematology
K S Peggs, S Mackinnon

Abstract

The dose escalation of chemoradiotherapy that is achievable with stem cell transplantation is often insufficient to eradicate malignancy, and an associated immune-mediated graft-versus-malignancy effect may be equally important for many diseases. The most directly compelling evidence for its presence is the efficacy of donor lymphocyte infusions in generating anti-tumor responses, particularly for relapsed chronic-phase chronic myeloid leukemia. Response rates and durability appear lower with myeloma and acute myeloid leukemia and myelodysplasia syndrome, and minimal with acute lymphoblastic leukemia. There is relatively little data on indolent lymphoid malignancies. Issues that remain to be resolved include the precise nature of the effector cells and their target antigens, the best strategies for separating graft-versus-malignancy from graft-versus-host disease (GVHD) and their effect on the durability of responses, and the role of adjuvant chemotherapy/cytokines. Similar issues surround routine combination with nonmyeloablative transplantation protocols and preliminary data suggests that GVHD may continue to provide a major obstacle.

References

Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N T UenoR E Champlin
Mar 12, 1999·Annual Review of Medicine·D L Porter, J H Antin
Jun 3, 1999·The New England Journal of Medicine·E C GuinanJ G Gribben
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·D BonnetS R Riddell
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D L PorterJ H Antin
Mar 21, 2000·Bone Marrow Transplantation·A M CarellaR Storb
Aug 5, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·E OrsiniJ Ritz
Sep 28, 2000·Current Opinion in Immunology·S Slavin
Oct 6, 2000·Bone Marrow Transplantation·R H CollinsP Parker
Jan 10, 2001·Bone Marrow Transplantation·M SalamaR H Collins

❮ Previous
Next ❯

Citations

May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Fiona J Clark, Ronjon Chakraverty
Mar 4, 2006·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·Rinat EshelElizabeth Naparstek
Apr 14, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Zeynep Arzu YeginGülsan Türköz Sucak
Jan 10, 2003·Clinical and Experimental Immunology·E C MorrisH J Stauss
Feb 12, 2004·Pediatric Transplantation·Mark P Atlas, Jeffrey M Lipton
Feb 12, 2004·Pediatric Transplantation·Kim VettenrantaUlla M Saarinen-Pihkala
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stella M DaviesNancy A Kernan
May 21, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Faith M YoungCraig A Mullen
Jul 17, 2008·Biological Chemistry·Ibrahim AlkatoutSanjay Tiwari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.